SHUKRAPHAR
Shukra Pharmaceuticals share price & financials
- Price
- ₹33.34
- Market cap
- ₹2.4k Cr
- Sector
- Healthcare
Quarterly results
Q1 FY27: revenue up 380.0%, net profit up 1400.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6 | 11 | 13 | 5 | 6 +0% | 39 +255% | 6 −54% | 24 +380% |
| EBITDA | 1 | 4 | 7 | 1 | 0 −100% | 27 +575% | 1 −86% | 21 +2000% |
| Net profit | 1 | 3 | 5 | 1 | 2 +100% | 20 +567% | -2 −140% | 15 +1400% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +98.0% 1Y
1Y: ₹27.24 on 10 Sept 2025 → ₹53.94. High ₹62.36 (30 Dec 2025), low ₹27.23 (26 May 2026).
Financials, as filed
Revenue fell 13.6% a year over 2 years, FY24 to FY26. Operating margin widened to 51.8%.
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹75 Cr | ₹33 Cr | ₹56 Cr |
| Operating profit | ₹19 Cr | ₹13 Cr | ₹29 Cr |
| Operating margin | 25.3% | 39.4% | 51.8% |
| Interest | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Depreciation | ₹3 Cr | ₹4 Cr | ₹4 Cr |
| Net profit | ₹18 Cr | ₹9 Cr | ₹21 Cr |
| Net margin | 24.0% | 27.3% | 37.5% |
| Cash from operations | ₹-5 Cr | ₹8 Cr | ₹3 Cr |
| Free cash flow | ₹-7 Cr | ₹5 Cr | ₹-13 Cr |
| ROCE | 44.0% | 22.0% | 37.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹2 Cr | ₹2 Cr | ₹4 Cr | ₹11 Cr | ₹44 Cr | ₹44 Cr |
| Reserves | ₹14 Cr | ₹15 Cr | ₹21 Cr | ₹47 Cr | ₹22 Cr | ₹46 Cr |
| Borrowings | ₹10 Cr | ₹3 Cr | ₹5 Cr | ₹3 Cr | ₹4 Cr | ₹5 Cr |
| Other liabilities | ₹10 Cr | ₹15 Cr | ₹45 Cr | ₹17 Cr | ₹18 Cr | ₹23 Cr |
| Total liabilities | ₹36 Cr | ₹35 Cr | ₹75 Cr | ₹78 Cr | ₹87 Cr | ₹117 Cr |
| Fixed assets | ₹18 Cr | ₹18 Cr | ₹20 Cr | ₹20 Cr | ₹19 Cr | ₹22 Cr |
| Capital work in progress | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹12 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹16 Cr | ₹16 Cr | ₹53 Cr | ₹56 Cr | ₹66 Cr | ₹84 Cr |
| Total assets | ₹36 Cr | ₹35 Cr | ₹75 Cr | ₹78 Cr | ₹87 Cr | ₹117 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Aug 2026
Since Sep 2025, promoters added +0.21 pp while the public trimmed −0.19 pp. The shareholder count grew 32% to 28,384.
- Promoters
- 51.2%
- DIIs
- 0.1%
- Public
- 48.7%
Since Sep 2025
- Promoters +0.21 pp
- Public −0.19 pp
- DIIs 0.00 pp
How it drifted, 12 quarters
Ownership split by quarter, oldest first. Dec '23: Promoters 51.0%, DIIs 0.1%, Public 48.9%.Mar '24: Promoters 51.0%, DIIs 0.1%, Public 48.9%.Jun '24: Promoters 51.0%, DIIs 0.1%, Public 48.9%.Sep '24: Promoters 51.0%, DIIs 0.1%, Public 48.9%.Dec '24: Promoters 51.0%, DIIs 0.1%, Public 48.9%.Mar '25: Promoters 51.0%, DIIs 0.1%, Public 48.9%.Jun '25: Promoters 51.0%, DIIs 0.1%, Public 48.9%.Sep '25: Promoters 51.0%, DIIs 0.1%, Public 48.9%.Dec '25: Promoters 51.0%, DIIs 0.1%, Public 48.9%.Mar '26: Promoters 51.0%, DIIs 0.1%, Public 48.9%.Jun '26: Promoters 51.0%, DIIs 0.1%, Public 48.9%.Aug '26: Promoters 51.2%, DIIs 0.1%, Public 48.7%.
Who bought this quarter
since Jun 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Parshva Texchem India Private Ltd. +0.21 pp 17.38% held
- Dakshesh Rameshchandra Shah +0.11 pp 1.11% held
The same filing shows 3 holders trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Aug 2026 filing
Every holder of Shukra Pharmaceuticals Limited above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| Renuka Yogesh Parikh | 19.11% | −0.07 pp |
| Yogesh Biharilal Parikh | 19.06% | −0.08 pp |
| Anar Project Private Limited | 18.71% | −0.07 pp |
| Parshva Texchem India Private Ltd. | 17.38% | +0.21 pp |
| Navkar Surgical Gujarat Limited | 11.74% | unchanged |
| Dakshesh Rameshchandra Shah | 1.11% | +0.11 pp |
| Anar Jayeshbhai Patel | 0.99% | unchanged |
| Sujay Jyotindra Mehta | 0.71% | unchanged |
| Payal Sujay Mehta | 0.52% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Shukra Pharmaceuticals Limited
Guides on how to read this kind of business and the numbers that matter.